Table 2.
Condition | 60 day case fatalities | March 2017 to February2018 | March 2018 to February 2019 | March 2019 to February 2020 | March 2020 to February 2021 | Model 1* | Model 2* | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Adjusted odds ratio (95% CI) | P value | Adjusted odds ratio (95% CI) | P value | ||||||||
Sepsis | No of deaths/cases | 148/11 722 | 163/12 028 | 158/11 402 | 110/7798 | 1.03 (0.84 to 1.27) | 0.77 | 1.00 (0.81 to 1.24) | 0.98 | ||
Rate per 10 000 cases (95% CI) | 126 (107 to 148) | 136 (116 to 158) | 139 (118 to 162) | 141 (116 to 170) | |||||||
Meningitis | No of deaths/cases | 29/3976 | 38/3899 | 31/3875 | 21/1964 | 1.28 (0.79 to 2.05) | 0.31 | 1.07 (0.66 to 1.73) | 0.78 | ||
Rate per 10 000 cases (95% CI) | 73 (49 to 105) | 97 (69 to 134) | 80 (54 to 113) | 107 (66 to 163) | |||||||
Bronchiolitis | No of deaths/cases | 69/46 614 | 55/53 703 | 65/54 648 | 16/9423 | 1.35 (0.81 to 2.26) | 0.25 | 1.18 (0.71 to 1.98) | 0.52 | ||
Rate per 10 000 cases (95% CI) | 15 (12 to 19) | 10 (8 to 13) | 12 (9 to 15) | 17 (10 to 28) | |||||||
Pneumonia | No of deaths/cases | 196/16 257 | 212/16 261 | 172/16 692 | 156/6540 | 1.71 (1.43 to 2.05) | P<0.001 | 1.62 (1.35 to 1.94) | P<0.001 | ||
Rate per 10 000 cases (95% CI) | 121 (104 to 139) | 130 (114 to 149) | 103 (88 to 120) | 239 (203 to 278) | |||||||
Viral wheeze | No of deaths/cases | 17/74 489 | 14/81 722 | 14/76 254 | 9/34 367 | 1.47 (0.71 to 3.01) | 0.30 | 1.51 (0.73 to 3.1) | 0.26 | ||
Rate per 10 000 cases (95% CI) | 2 (1 to 4) | 2 (1 to 3) | 2 (1 to 3) | 3 (1 to 5) | |||||||
Upper RTI | No of deaths/cases | 40/55 369 | 42/59 138 | 26/60 208 | 15/19 677 | 1.22 (0.71 to 2.09) | 0.48 | 1.19 (0.69 to 2.04) | 0.53 | ||
Rate per 10 000 cases (95% CI) | 7 (5 to 10) | 7 (5 to 10) | 4 (3 to 6) | 8 (4 to 13) |
RTI=respiratory tract infection.
Model 1: adjusted for age and sex; model 2: adjusted for age, sex, and comorbidities in table 1. All odds ratios compare 60 day case fatality from March 2020 to February 2021 with reference period from March 2017 to February 2020.